论文部分内容阅读
目的:探讨贝伐珠单抗单药及其与伊立替康、司莫司汀、顺铂联合方案在复发性高级别胶质瘤患者中的疗效。方法:回顾性分析自2011年1月到2019年11月于北京协和医院神经外科接受贝伐珠单抗单药及其与伊立替康、司莫司汀、顺铂联合方案治疗的70例复发性高级别胶质瘤患者(38例接受贝伐珠单抗单药治疗，13例接受贝伐珠单抗-司莫司汀联合治疗，11例接受贝伐珠单抗-顺铂联合治疗，8例接受贝伐珠单抗-伊立替康联合治疗)的生存状况(无进展生存期、总生存期)。结果:70例患者的中位总生存期为12.83个月，中位无进展生存期为6.23个月。贝伐珠单抗单药组的中位总生存期为10.92个月，中位无进展生存期为5.03个月；贝伐珠单抗-司莫司汀联合组的中位总生存期为16.30个月，中位无进展生存期为6.77个月；贝伐珠单抗-伊立替康联合组的中位总生存期为11.90个月；贝伐珠单抗-顺铂联合组的中位总生存期为14.40个月。结论:贝伐珠单抗相关治疗方案均可有效提高患者的无进展生存期，可以推荐用于复发性高级别胶质瘤患者的治疗。“,”Objective:To explore the efficacies of bevacizumab monotherapy and combination therapy of bevacizumab with irinotecan, semustine and cisplatin in patients with recurrent high-grade glioma.Methods:Seventy patients with recurrent high-grade glioma admitted to our hospital from January 2011 to November 2019 were chosen in our study; 38 patients received bevacizumab monotherapy, 13 patients accepted bevacizumab and semustine combination therapy, 11 patients received bevacizumab and cisplatin combination therapy, and 8 patients accepted bevacizumab and irinotecan combination therapy. Survival statuses (progression-free survival [PFS] and overall survival [OS]) of these patients were retrospectively analyzed.Results:The median OS and median PFS of the enrolled patients were 12.83 months and 6.23 months, respectively. The median OS and median PFS of patients accepted bevacizumab monotherapy were 10.92 months and 5.03 months, respectively. The median OS and median PFS of patients accepted bevacizumab and semustine combination therapy were 16.30 months and 6.77 months, respectively. The median OS in patients accepted bevacizumab and irinotecan combination therapy and patients accepted bevacizumab and cisplatin combination therapy was 11.90 months and 14.40 months, respectively.Conclusion:Bevacizumab by different therapy methods enjoys good efficacy; bevacizumab monotherapy or combination therapy can be recommended for recurrent high-grade glioma.